Thomas A. Werfel

Thomas A. Werfel

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 404 publications

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Journal: Allergologie select

Published: May 06, 2026

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.

Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.

Journal: Acta dermato-venereologica

Published: April 16, 2026

Reduced NK cell frequency in older patients with evolving fractures is linked to a distinct inflammatory cytokine profile.

Reduced NK cell frequency in older patients with evolving fractures is linked to a distinct inflammatory cytokine profile.

Journal: Immunity & ageing : I & A

Published: March 27, 2026

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.

Journal: Acta dermato-venereologica

Published: March 26, 2026

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: An analysis from the TREATKids registry.

Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: An analysis from the TREATKids registry.

Journal: The Journal of investigative dermatology

Published: March 26, 2026

Patient treatment needs in atopic dermatitis: A real-world cohort study.

Patient treatment needs in atopic dermatitis: A real-world cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 15, 2026

The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA2LEN ADCARE statement paper.

The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA2LEN ADCARE statement paper.

Journal: The World Allergy Organization journal

Published: January 28, 2026

Staphylococcus aureus serine protease-like protein B elicits a type 1/type 2 immune response in atopic dermatitis patients.

Staphylococcus aureus serine protease-like protein B elicits a type 1/type 2 immune response in atopic dermatitis patients.

Journal: Frontiers in immunology

Published: January 28, 2026

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.

Journal: Skin health and disease

Published: November 28, 2025

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany.

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany.

Journal: Acta dermato-venereologica

Published: November 26, 2025

Patch Test Results With the European Baseline Series, 2021/2022-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Patch Test Results With the European Baseline Series, 2021/2022-Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC.

Journal: Contact dermatitis

Published: November 14, 2025

Thymic stromal lymphopoietin (TSLP) - pro-inflammatory cytokine and antimicrobial peptide.

Thymic stromal lymphopoietin (TSLP) - pro-inflammatory cytokine and antimicrobial peptide.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: October 31, 2025

Showing 1-12 of 404

Last Updated: 09/26/2026